Jose G Diez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jose G Diez has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Bernardo Lombo
Department of Medicine, Yale School of Medicine, New Haven, CT, USA
1 shared publication
Latest Publications
- 11 June 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 224, 22-23
The high stakes of performing transcatheter aortic valve replacement in the low surgical risk patient
- 11 June 2024
- Published by Elsevier in The American Journal of Cardiology
- Vol. 224, 22-23
The high stakes of performing transcatheter aortic valve replacement in the low surgical risk patient
- 1 January 2013
- Vol. 40 (3) , 298-301
Transcatheter aortic valve implantation (TAVI): the hype and the hope.
- 1 January 2013
- Vol. 40 (3) , 298-301
Transcatheter aortic valve implantation (TAVI): the hype and the hope.
- Open Access
- 1 March 2011
- Published by Taylor & Francis in Core Evidence
- Vol. 6, 31-42
Ticagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. Aims: To update the evidence and provide an overview of the available data on ticagrelor. Evidence review: Peer reviewed articles published and listed under Medline Search, and published updated guidelines for pharmacotherapies in acute coronary syndromes were reviewed. Place in therapy: Clinical evidence is increasing to support the use of new thienopyridines and the direct-acting P2Y12 receptor in the setting of acute coronary syndromes. Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.
- 1 March 2011
- Published by Taylor & Francis in Core Evidence
- Vol. 6, 31-42
Open AccessTicagrelor: the evidence for its clinical potential as an oral antiplatelet treatment for the reduction of major adverse cardiac events in patients with acute coronary syndromes
Introduction: Ticagrelor, the first direct-acting, reversibly binding oral P2Y12 receptor antagonist, appears to have a favorable efficacy and safety profile. Aims: To update the evidence and provide an overview of the available data on ticagrelor. Evidence review: Peer reviewed articles published and listed under Medline Search, and published updated guidelines for pharmacotherapies in acute coronary syndromes were reviewed. Place in therapy: Clinical evidence is increasing to support the use of new thienopyridines and the direct-acting P2Y12 receptor in the setting of acute coronary syndromes. Conclusion: The options for drugs to inhibit the platelet P2Y12 receptor for adenosine diphosphate are rapidly expanding. Ticagrelor has shown benefits in clinical trials. Its rapid onset of platelet inhibition and short half-life make it an attractive alternative to thienopyridines, especially when rapid inhibition of platelet aggregation or its quick reversal are required.